Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B

Journal of Medical Virology

Volumn 54, Issue 3, 1998, Pages 167-172

  Artillo, Santiago ^a   Pastore, Giuseppe ^b   Alberti, Alfredo ^c   Milella, Michelle ^b   Santantonio, Teresa ^b   Fattovich, Giovanna ^d   Giustina, Giuliano ^c   Ryff, Jean Charles ^e   Chaneac, Monique ^e   Bartolomé, Javier ^a   Carreño, Vicente ^a,f  

^a Fundacion Estudio Hepatitis Virales   (Spain)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Antiviral therapy; Hepatitis B virus

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; PLACEBO; RECOMBINANT INTERLEUKIN 2; VIRUS DNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INJECTION PAIN; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; DNA, VIRAL; DOUBLE-BLIND METHOD; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

HEPATITIS B VIRUS;

EID: 0031912950     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199803)54:3<167::AID-JMV4>3.0.CO;2-3     Document Type: Article

References (18)

1. Anastassakos Ch, Alexander GJM, Wolstencroft RA, Auery JA, Portmann BC, Panayi GS, Dumonde DC, Eddleston ALWF, Williams R (1988): Interleukin 1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology 94:999-1005.
2. Brook MG, Karayiannis P, Thomas HC (1989): Which patients with chronic hepatitis B will respond to alpha interferon therapy?. A statistical analysis of predictive factors. Hepatology 10:761-763.
3. Bruch HR, Korn A, Klein H, Markus R, Malmus K, Baumgarten R, Müller R (1993): Treatment of chronic hepatitis B with interferon alpha-2b and interleukin 2. Journal of Hepatology 17:S52-S55.
4. Chu CM, Shyu WCh, Kuo RW, Liaw YF (1987): HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection. Its role in the pathogenesis of chronic type B hepatitis. Hepatology 1:1311-1316.
5. Hoofnagle J, Hanson R, Minuk GY, Papas SCh, Schafer DF, Dusheiko GM, Straus SE, Popper H, Jones EA (1984): Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86:150-157.
6. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi U, Di Bisceglie A, Mallahan C, Park Y, Meschievitz C, Jones EA (1988): Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325.
7. Ikeda I, Lever AML, Thomas HC (1986): Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 6:962-965.
8. Kakumu S, Fuji A, Yoshioka K, Tahara H, Ohtani Y, Hirofuji H, Murase K, Aoi T (1988): Pilot study of recombinant human interleukin-2 for chronic type B hepatitis. Hepatology 8:487-492.
9. Mizoguchi Y, Shin T, Sakagami Y, Seki S, Kuroki T, Kobayashi K, Yamamoto S, Morisawa S (1988): Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis. Gastroenterology Japanese 23:147-152.
10. Mutchnick N, Appelman H, Chung H, Aragona E, Gupta TP, Cummings GD, Waggoner JG, Hoofnagle JH, Shafritz DA (1991): Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology 14:409-415.
11. Nishioka M, Kagawa H, Shirai M, Terada S, Watanabe S (1987): Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: A preliminary report. American Journal of Gastroenterology 82:438-442.
12. Oda K, Asao H, Higuchi M, Tanaka N, Moffat S, Nakamura M, Tabayashi K, Sugamura K (1997): Induction of IL-1 beta-converting enzyme-independent apoptosis by IL-2 in human T cell lines. International Immunology 9:1303-1310.
13. Poitrine A, Chousterman S, Chousterman M, Naveau S, Thang MN, Chaput JC (1985): Lack of in vivo activation of the interferon system in HBsAg-positive chronic active hepatitis. Hepatology 5:171-174.
14. Price JS, France AJ, Moaven LD, Welsby PD (1986): Foscarnet in fulminant hepatitis B. The Lancet ii:1273.
15. Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A (1980): Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B infection. Gastroenterology 79:195-199.
16. Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC (1987): Lymphoblastoid interferon therapy of chronic HBV infection: a comparison of 12 versus 24 weeks of thrice weekly treatment. Journal of Hepatology 5:51-58.
17. Smicht CI, Weissberg J, Bernhardt L, Gregory PB, Robinson WS, Merigan TC (1983): Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B infection. Journal of Infectious Diseases 148:907-913.
18. Vogel W, Tilg H, Tratkiewicz J, Herold M, Aulitzky WE, Geissler D, Judmaier G, Huber C (1989): Natural interleukin-2 in chronic hepatitis B: Phase I study. Hepatology 10:698.